Precision BioSciences IncNASDAQ:DTIL
- LAST PRICE9.3850
- TODAY'S CHANGE (%)-0.2850 (-2.9473%)
- Bid / Lots9.3500/ 49
- Ask / Lots9.4600/ 3
- Open / Previous Close9.6000 / 9.6700
- Day Range
- 52 Week Range
- Volume19,410
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DTIL |
|---|---|---|
| 09:32 ET | 308 | 9.6 |
| 09:54 ET | 1450 | 9.71 |
| 09:56 ET | 300 | 9.69 |
| 10:08 ET | 100 | 9.6502 |
| 10:10 ET | 200 | 9.69 |
| 10:33 ET | 412 | 9.61 |
| 10:42 ET | 500 | 9.7689 |
| 11:00 ET | 100 | 9.61 |
| 11:08 ET | 2907 | 9.52 |
| 11:09 ET | 100 | 9.4206 |
| 11:11 ET | 255 | 9.42 |
| 11:15 ET | 444 | 9.445 |
| 11:24 ET | 419 | 9.4536 |
| 11:36 ET | 794 | 9.316 |
| 11:47 ET | 400 | 9.3001 |
| 12:03 ET | 432 | 9.25 |
| 12:16 ET | 100 | 9.3 |
| 12:23 ET | 435 | 9.3498 |
| 12:30 ET | 100 | 9.3 |
| 12:38 ET | 100 | 9.3 |
| 12:41 ET | 100 | 9.3 |
| 01:01 ET | 100 | 9.25 |
| 01:24 ET | 100 | 9.2458 |
| 01:28 ET | 100 | 9.24 |
| 01:33 ET | 100 | 9.23 |
| 01:42 ET | 400 | 9.23 |
| 01:46 ET | 100 | 9.2249 |
| 02:04 ET | 100 | 9.2 |
| 02:09 ET | 868 | 9.1715 |
| 02:11 ET | 242 | 9.19 |
| 02:15 ET | 400 | 9.24 |
| 02:20 ET | 100 | 9.205 |
| 02:33 ET | 100 | 9.385 |
Today
Jun 20, 2024
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness, from 7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 5, 2024
May 30, 2024
DJ Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co., from 7:20AM ET on Thursday May 30, 2024 by Dow Jones
7:20AM ET on Thursday May 30, 2024 by Dow JonesPrecision BioSciences to Participate in Upcoming June Investor Conferences, from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Precision BioSciences Inc | 67.0M | -1.7x | --- |
Champions Oncology Inc | 67.4M | -7.2x | --- |
MEI Pharma Inc | 19.1M | 0.7x | --- |
RVL Pharmaceuticals PLC | 110.0 | 0.0x | --- |
Neptune Wellness Solutions Inc | 73.4K | 0.0x | --- |
Repare Therapeutics Inc | 144.7M | -3.2x | --- |
Company Information
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision. ARCUS particularly generates defined outcomes due to predominant repair using homology directed repair (HDR) as opposed to non-homologous end joining (NHEJ). The Company’s in vivo gene editing programs include PBGENE-HBV, PBGENE-PMM, PBGENE-NVS, PBGENE-DMD, PBGENE-LL2, PBGENE-LL3 and iECURE-OTC. PBGENE-HBV program is designed for the potential treatment of chronic hepatitis B virus (HBV). The Company is pursuing development of PBGENE-PMM as a potential opportunity for treatment of m.3243 associated primary mitochondrial myopathy (PMM).
Contact Information
- Headquarters
- 302 E Pettigrew St Ste A100DURHAM, NC, United States 27701-2393
- Phone
- 919-314-5512
- Fax
- 480-393-5553
Executives
- Independent Chairman of the Board
- Kevin Buehler
- President, Chief Executive Officer, Director
- Michael Amoroso
- Chief Financial Officer
- Alex Kelly
- General Counsel, Secretary
- Dario Scimeca
- Chief Medical Officer
- Alan List
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $67.0M |
|---|---|
Revenue (TTM) | $57.5M |
Shares Outstanding | 6.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.73 |
EPS | $-5.50 |
Book Value | $4.53 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | 1.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -60.09% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
